These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28301423)

  • 1. No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy.
    Mota TM; Rasmussen TA; Rhodes A; Tennakoon S; Dantanarayana A; Wightman F; Hagenauer M; Roney J; Spelman T; Purcell DFJ; McMahon J; Hoy JF; Prince HM; Elliott JH; Lewin SR
    AIDS; 2017 May; 31(8):1137-1141. PubMed ID: 28301423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
    PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts.
    Cao W; Mehraj V; Trottier B; Baril JG; Leblanc R; Lebouche B; Cox J; Tremblay C; Lu W; Singer J; Li T; Routy JP; ; Vézina S; Charest L; Milne M; Huchet E; Lavoie S; Friedman J; Duchastel M; Villielm F; Côté P; Potter M; Lessard B; Charron MA; Dufresne S; Turgeon ME; Rouleau D; Labrecque L; Fortin C; de Pokomandy A; Hal-Gagné V; Munoz M; Deligne B; Martel-Laferrière V; Gilmore N; Fletcher M; Szabo J
    Clin Infect Dis; 2016 Jan; 62(2):250-257. PubMed ID: 26349551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
    Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
    J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial of lovastatin in HIV-infected, HAART naïve patients (NCT00721305).
    Montoya CJ; Higuita EA; Estrada S; Gutierrez FJ; Amariles P; Giraldo NA; Jimenez MM; Velasquez CP; Leon AL; Rugeles MT; Jaimes FA
    J Infect; 2012 Dec; 65(6):549-58. PubMed ID: 23085245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression.
    Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT
    Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression.
    Serrano-Villar S; Gutiérrez C; Vallejo A; Hernández-Novoa B; Díaz L; Abad Fernández M; Madrid N; Dronda F; Zamora J; Muñoz-Fernández MÁ; Moreno S
    J Infect; 2013 Jan; 66(1):57-66. PubMed ID: 23046968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy.
    Zaegel-Faucher O; Bregigeon S; Cano CE; Obry-Roguet V; Nicolino-Brunet C; Tamalet C; Dignat-George F; Poizot-Martin I
    AIDS; 2015 Jul; 29(12):1505-10. PubMed ID: 26244390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
    Silveira MP; Silveira CP; Guttier MC; Page K; Moreira LB
    J Clin Pharm Ther; 2016 Dec; 41(6):689-694. PubMed ID: 27676134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
    Fidler S; Stöhr W; Pace M; Dorrell L; Lever A; Pett S; Kinloch-de Loes S; Fox J; Clarke A; Nelson M; Thornhill J; Khan M; Fun A; Bandara M; Kelly D; Kopycinski J; Hanke T; Yang H; Bennett R; Johnson M; Howell B; Barnard R; Wu G; Kaye S; Wills M; Babiker A; Frater J;
    Lancet; 2020 Mar; 395(10227):888-898. PubMed ID: 32085823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
    Orrell C; Harling G; Lawn SD; Kaplan R; McNally M; Bekker LG; Wood R
    Antivir Ther; 2007; 12(1):83-8. PubMed ID: 17503751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy.
    Leth S; Nymann R; Jørgensen S; Olesen R; Rasmussen TA; Østergaard L; Denton PW; Tolstrup M; Søgaard OS
    AIDS; 2016 Mar; 30(5):713-21. PubMed ID: 26595541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control study.
    Yue Y; Wang N; Han Y; Zhu T; Xie J; Qiu Z; Song X; Li Y; Routy JP; Wang J; Li T
    BMC Infect Dis; 2017 Dec; 17(1):771. PubMed ID: 29246197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?
    Girard PM; Nelson M; Mohammed P; Hill A; van Delft Y; Moecklinghoff C
    AIDS; 2013 Nov; 27(17):2759-63. PubMed ID: 23842127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.